Antiangiogenic therapy for cancer: an update.
Antiangiogenic therapy for cancer: an update.
复制标题
DOI:
10.1002/phar.1147
复制
发表时间:
2012-12
期刊:
影响因子:
4.1
通讯作者:
Somanath, Payaningal R.
中科院分区:
文献类型:
--
作者:
Al-Husein, Belal;Abdalla, Maha;Trepte, Morgan;DeRemer, David L.;Somanath, Payaningal R.
The idea of anti-angiogenic therapy was the brain child of Dr. Judah Folkman in the early 1970s. He proposed that by cutting the blood supply off, cancer cells can be deprived of nutrients and hence treated. His efforts were paid off when Bevacizumab (Avastin®), a monoclonal antibody against the vascular endothelial growth factor (VEGF) was first approved for anti-angiogenic therapy in 2004 for the treatment of breast cancer. Since then, an array of anti-angiogenic inhibitors were developed, used in clinical trials and many got approved for use for the treatment of multiple cancers, alone or in combination with other cytotoxic/chemotherapy drugs. Despite this important breakthrough, anti-angiogenic therapy for cancer met with a number of hurdles on its way to be one of the options for cancer therapy. Herein, we summarize the latest update on the current knowledge on the mechanisms of tumor angiogenesis, pro- and anti-angiogenic factors, potential targets and their mechanisms of action, experimental evidences and the most recent data on the clinical trials on anti-angiogenic agents for cancer therapy.
登录
查看更多内容
影响因子:
9.7
作者:
Acs, G;Chen, M;Koch, CJ
通讯作者:
Koch, CJ
影响因子:
50.5
作者:
Blumenschein, G. R., Jr.;Kabbinavar, F.;Schwartzberg, L.
通讯作者:
Schwartzberg, L.
影响因子:
45.3
作者:
Burstein, Harold J.;Elias, Anthony D.;Miller, Kathy D.
通讯作者:
Miller, Kathy D.
影响因子:
64.5
作者:
Fischer, Christian;Jonckx, Bart;Carmeliet, Peter
通讯作者:
Carmeliet, Peter
影响因子:
45.3
作者:
Escudier, Bernard;Eisen, Tim;Bukowski, Ronald M.
通讯作者:
Bukowski, Ronald M.